Evidence mapPaperPMID 41857071Full record

ReviewNature reviews. Disease primers2026

Type 2 diabetes mellitus.

Melanie J Davies, Soo Lim, Tommy Slater, Jonathan Goldney, Athena Philis-Tsimikas, Denise R Franco, Roberta Lamptey, Thomas Yates, Tsvetalina Tankova, Ildiko Lingvay

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Melanie J DaviesDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK. melanie.davies39@nhs.net.
Soo LimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.ORCID http://orcid.org/0000-0002-4137-1671
Tommy SlaterDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.ORCID http://orcid.org/0000-0003-2764-3148
Jonathan GoldneyDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.ORCID http://orcid.org/0000-0001-8553-8296
Athena Philis-TsimikasScripps Whittier Diabetes Institute, Scripps Health, San Diego, CA, USA.
Denise R FrancoCPClin/DASA Clinical Research Centre, São Paulo, Brazil.
Roberta LampteyKorle Bu Polyclinic Family Medicine Department, Korle Bu Teaching Hospital, Accra, Ghana.ORCID http://orcid.org/0000-0002-4260-9442
Thomas YatesDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.
Tsvetalina TankovaDepartment of Endocrinology, Faculty of Medicine, Medical University, Sofia, Sofia, Bulgaria.ORCID http://orcid.org/0000-0002-7572-1131
Ildiko LingvayDepartment of Internal Medicine/Endocrinology and Peter O'Donnel Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. Ildiko.Lingvay@UTSouthwestern.edu.ORCID http://orcid.org/0000-0001-7006-7401

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease driven by a complex interplay of genetic, biological, behavioural and social factors. The epidemiology of T2DM has shifted considerably, largely attributable to increasing obesity rates. Furthermore, T2DM prevalence is increasing in younger people (diagnosis <40 years of age; early-onset T2DM), which is associated with more aggressive disease progression, higher risk factor burden, earlier and more severe complications, and greater lifetime morbidity than later-onset T2DM. T2DM is traditionally associated with a high risk of microvascular and macrovascular complications, although rates of cardiovascular complications have reduced in some high-income countries. Currently, emerging and non-traditional diabetes complications, such as those related to mental health and cognitive function, are being recognized, and people with T2DM increasingly experience multimorbidity and reduced quality of life. Additionally, a growing prevalence of obesity has resulted in high rates of obesity-related complications. Novel therapies and technologies may offer considerable benefit, although socioeconomic disparities may exacerbate barriers to effective prevention and equitable access. The complex nature of T2DM and its comorbidities underscores the urgent need for a person-centred, holistic approach that integrates glucose and weight management with broader attention to comorbidities, 24-h physical behaviours, psychosocial well-being and social determinants of health.

Indexed as

Diabetes Mellitus, Type 2HumansObesityPrevalenceQuality of LifeRisk Factors

Identifiers

PMID41857071

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.